| Literature DB >> 26648113 |
Nobuyuki Horita1, Masaki Yamamoto1, Takashi Sato1, Toshinori Tsukahara1, Hideyuki Nagakura1, Ken Tashiro1, Yuji Shibata1, Hiroki Watanabe1, Kenjiro Nagai1, Kentaro Nakashima1, Ryota Ushio1, Misako Ikeda1, Kentaro Sakamaki2, Takashi Yoshiyama3, Takeshi Kaneko1.
Abstract
Since 2010, studies on the diagnostic accuracy of COBAS TaqMan MTB (CTM) have been frequently reported with an unignorable discrepancy. The key inclusion criterion for this systematic review was original studies that could provide sufficient data for calculating the sensitivity and the specificity of CTM for M tuberculosis (TB) or M tuberculosis complex. The reference test was Mycobacterium culture. We used bivariate model for meta-analyses. Of the 201 candidate articles, we finally identified 17 eligible articles.Concerning the respiratory specimens, 1900 culture positive specimens and 20983 culture negative specimens from 15 studies were assessed. This provided the summary estimate sensitivity of 0.808 (95% CI 0.758-0.850) and the summary estimate specificity of 0.990 (95% CI 0.981-0.994). The area under curve was 0.956. The diagnostic odds ratio was 459 (95% CI 261-805, I(2) 26%). For the smear positive respiratory specimens, the sensitivity was 0.952 (95% CI 0.926-0.969) and the specificity was 0.916 (95% CI 0.797-0.968). For the smear negative respiratory specimens, the sensitivity and the specificity were 0.600 (95% CI 0.459-0.726) and 0.989 (95% CI 0.981-0.993), respectively. The diagnostic accuracy was poorer for the non-respiratory specimens, than for the respiratory specimens, but was acceptable. We believe that the information obtained from this study will aid physicians' decision making.Entities:
Mesh:
Year: 2015 PMID: 26648113 PMCID: PMC4673449 DOI: 10.1038/srep18113
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Characteristics of the included studies.
| Author Year | Country (Income class) | Recruitment | Study design | Acid-fast stain | Specimen preparation for Cobas TaqMan | Culture | TB confirmation | Respiratory specimen | Non-respiratory specimen | Specimen number |
|---|---|---|---|---|---|---|---|---|---|---|
| Antonenka 2013 | Germany (A) | Specimen bank | R, F, I | AR | NALC-NaOH | MGIT, LJ | Genotype CM, Genotype MTBC | sp, ba | R 116 NR 0 | |
| Bloemberg 2013 | Switzerland (A) | Tertiary care diagnostic center | P, I | AR, ZN | NALC-NaOH | MGIT, 7H11 | 16SrRNA | sp, bal, ba, other | ti, ur, csf, ln, as, ab | R 829 NR 280 |
| Causse 2011 | Spain (A) | ? | AR | NALC-NaOH | 7H9, LJ, liquid medium | ? | csf, pf, ar, as, ln, ti, gf | R 0 NR 340 | ||
| Chandran 2010 | India (C) | Tb Control Program | Short article | ? | NALC-NaOH | LJ | Genotype MTBC | sp | R 72 NR 0 | |
| Cho 2015 | Korea (A) | University hospital | I | ? | NALC-NaOH | 2%Ogawa, MGIT | multiplex PCR | sp, ba, bl, bal, ts | pus, pf, csf, ur, ti, ab | R 2384 NR 626 |
| Choi 2013 | Korea (A) | ? | F, Korean, #1 | AR, ZN | NALC-NaOH | MGIT, 3%Ogawa | Seeplex | sp, bal | R 619 NR 0 | |
| Huh 2015 | Korea (A) | Tertiary care hospital | R #2 | AR, ZN | NALC-NaOH (2%) | Liquid, solid medium | cordF, MPT64, MTB-ID V3 | ? | R 6772 NR 0 | |
| Ikegame 2012 | Japan (A) | ? | R | AR | NaOH | ? | ? | sp, bal, bl | R 1745 NR 0 | |
| Jönsson 2015 | Sweden (A) | University hospital laboratory | R, I | ? | NALC-NaOH | LJ, MGIT | AccuProbe, 16SrRNA GenoType MTBC, | sp, bal, bl | bf, ti, ur, gf, csf | R 2388 NR 1005 |
| Kim JH 2011 | Korea (A) | Tertiary care hospital | P, I, #2 | ZN | NALC-NaOH | 3%Ogawa | Amplicor, history | sp, bal, pf | ar, as, bf, ti | R 92 NR 0 |
| Kim JW 2013 | Korea (A) | ? | F, #1 | ? | NALC-NaOH | MGIT | PCR assay Smear | bal, ba, sp | ab, csf, ar, as, pf, ti, ur | R 360 NR 65 |
| Lee 2013 | Taiwan (B) | University hospital & General hospital | P, I | AR, Ki | NALC-NaOH | MGIT, LJ | Middlebrook7H11 | sp | R 586 NR 0 | |
| Lim 2014 | Korea (A) | University hospital | P, B | ZN | NALC-NaOH (4%) | 3%Ogawa | ? | sp, bal | R 1167 NR 0 | |
| Linasmita 2012 | Thailand (B) | University hospital | P, I | ? | QIAGEN | MGIT | ? | cervical ln | R 0 NR 73 | |
| Park 2013 | Korea (A) | Terciary care hospital | P, B, #2 | AR,ZN | NALC-NaOH (2%) | MGIT, 3%Ogawa | cord F, conventional PCR MPT64, MTB-ID V3, | sp, bal | R 320 NR 0 | |
| Tortoli 2012 | Italy (A) | Reference center laboratory | R | AR | NALC-NaOH (1%) | MGIT, LJ | GenoType, 16SrRNA | bl, gf, sp | ti, bf, csf, pf, ab, ur | R 4340 NR 1727 |
| Yang 2011 | Taiwan (B) | University hospital laboratory | P | AR, Ki | NALC-NaOH | LJ, MGIT, 7H11 | MPT64, GenoType, Mycobacterium CM assay | su, ba, bal | R 1093 NR 0 |
Income class: The World Bank income classification. A, high-income economy; B, upper-middle-income economy; C, lower-middle-income economy; D, low-income economy. Taiwan was classified as China for this table.
Study design: P, prospective study; R, retrospective study; F, using frozen specimen; B, TaqMan MTB was conducted blindly; I, invalid rate was reported; if these information was not provided, left blank. Short article and non-English article were also mentioned. #1, Choi and Kim JW used data from same hospital in different time. #2, Huh, Kim JH, and Park used data from same hospital in different time.
Acid-fast stain: ZN, Ziehl-Neelsen; AR, auramine-rhodamine; Ki, Kinyoun.
Specimen preparation for Cobas TaqMan: NALC-NaOH, N-acetyl-l-cysteine with sodium hydroxide; NaOH, sodium hydroxide.
Culture: MGIT, Mycobacteria Growth Indicator Tube; LJ, Löwenstein-Jensen; 7H9, Middlebrook 7H9 Broth; 7H10/11, Middlebrook 7H10/11 Agar; BacT/A, BacT/Alert.
Tb confirmation: 16SrRNA, 16S rRNA gene sequence; cordF, cord formation.
Respiratory specimen: sp, sputum; ba, broncheal/tracheal aspirate; bl, broncheal/tracheal lavage; bal, bronchialalveolar lavage; gf, gastric fluid; ts, throat swab.
Non-respiratory specimen: ln, lymph node; pf, pleural fluid; ar, articular fluid; as, ascite fluid; ab, abcess/pus; ur, urine; csf, cerebrospinal fluid; bf, body fluid; bl, blood; gf, gastric fluid; ti, other tissue sample.
Specimen number: R, number of the respiratory specimens; NR, number of the non-respiratory specimens.
Figure 1The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
Summary of the results.
| Specimen type | Study n | Specimen n | Sensitivity (95% CI) | Specificity (95% CI) | DOR (95% CI), I2 | AUC |
|---|---|---|---|---|---|---|
| Respiratory | 15 | 22883 | 0.808 (0.758–0.850) | 0.990 (0.981–0.994) | 459 (261–805), 26% | 0.956 |
| Respiratory, smear+ | 7 | 821 | 0.952 (0.926–0.969) | 0.916 (0.797–0.968) | 269(66–1104), 0% | 0.961 |
| Respiratory, smear– | 7 | 11621 | 0.600 (0.459–0.726) | 0.989 (0.981–0.993) | 132 (71–243), 14% | 0.971 |
| Non–respiratory | 7 | 4116 | 0.586 (0.437–0.721) | 0.984 (0.955–0.994) | 86 (34–217), 7% | 0.898 |
DOR: diagnostic odds ratio. I2: Higgins’ heterogeneity. AUC: area under receiver operating characteristics curve.
Figure 2The paired forest plot for the diagnostic accuracy.
TP: true positive. FP: false positive. FN: false negative. TN: true negative.
Figure 3The summary receiver operating characteristics curves.
SROC: summary receiver operation characteristics curve. conf. region: confidence region. sm+, smear positive. sm−, smear negative.
Figure 4The forest plot for invalid rate.
Valid: sum of positive and negative results.